Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
Part of paid clinical trials in Omaha, Nebraska.
- Sponsor
- University of Nebraska
- Study ID
- NCT02204683
- Phase
- PHASE1
- Status
- Completed
Conditions
- Neovascular Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept — DRUGIntravitreal aflibercept
Study Details
The main goal is to study way that aflibercept injection behaves in the eye and in the body of patients with wet macular degeneration, in patients who have had previous vitreous removal surgery.
Key Dates
- Start date
- Sep 5, 2014
- Status verified
- Sep 2023
- Primary completion
- Dec 14, 2016
- Completion
- Dec 14, 2016
Study Design
- Enrollment
- 5 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Other: AfliberceptSubjects who have had a vitrectomy previously
- Other: Aflibercept in Non-Vitrectomized eyesPatients who have not had vitrectomy.
Primary Outcome Measure
Pharmacokinetic (PK) aflibercept aqueous [ Time Frame: 28 days ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Nebraska Medical Center, Truhlsen Eye Institute | Omaha | Nebraska | 68105 | - |